ST. LOUIS , Feb. 23 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health, announced today that its first multiple sclerosis (MS) patient has had no relapses for the past 16 months since beginning GenoMed's protocol in October, 2004.

On October 31, 2005 , the patient, a young white woman, wrote:

'Just wanted to share with you that I have just had my first full year with no exacerbations of multiple sclerosis. This has never happened for me since I was diagnosed eight years ago. I have always experienced at the very least two exacerbations each year; Sept/Oct and Dec/Jan without fail, until this last year.

'I have had every reason to have an exacerbation, particularly this year ... This has been an incredibly stressful summer and fall. I recently felt extremely tired, as though an exacerbation was imminent, and made sure to get extra rest but never experienced a recurrence. As you well know no one can 'will' an exacerbation to go away, and extra rest will not stave it off.'

On February 6, 2006 she wrote: 'I am feeling great! I haven't had an exacerbation in over 2 years, and have more energy than ever.'

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, 'Relapsing, remitting MS is a hard disease to know how to treat because it waxes and wanes so much anyway. This case report is encouraging because the patient had regular relapses every 6 months in the past, and none for the past 16 months. Of course, we need to see if our protocol continues to work in this patient, as well as in additional patients. But ours could be one of the more effective treatments for multiple sclerosis yet. It would clearly be one of the least toxic and expensive.'

About GenoMed

GenoMed owns patents pending for the use of already existing, safe blood pressure pills to treat many diseases besides high blood pressure, including autoimmune diseases like MS. To enroll in GenoMed's trial, please contact Dr. Moskowitz at dwmoskowitz@genomed.com . GenoMed conducts trials for free, and then charges $800 per patient per year once results have been published.

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases 'ought to,' 'should,' 'could,' 'may,' or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed